Mohamed Hatmi
Overview
Explore the profile of Mohamed Hatmi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
237
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chaari M, Ayadi I, Rousseau A, Lefkou E, Van Dreden P, Sidibe F, et al.
BMC Cancer
. 2014 Dec;
14:991.
PMID: 25535397
Background: In breast cancer patients routine thromboprophylaxis is not recommended but individualized risk assessment is encouraged. The incorporation of hypercoagulability biomarkers could increase the sensitivity of risk assessment models (RAM)...
2.
Elalamy I, Gkalea V, Gerotziafas G, Ketatni H, Hatmi M
Ann Biol Clin (Paris)
. 2013 Nov;
71:47-57.
PMID: 24235328
Platelets play a pivotal role in the regulation of both thrombosis and haemostasis. Functional testing of platelet response has been exclusively used in the diagnosis and management of bleeding disorders....
3.
Papageorgiou C, Vandreden P, Marret E, Bonnet F, Robert F, Spyropoulos A, et al.
Thromb Res
. 2013 Oct;
132(5):584-91.
PMID: 24094602
Background: Patients with lung adenocarcinoma undergoing surgery are in high risk for VTE and receive routine post-operative thromboprophylaxis with LWMH. Aim: We investigated markers of hypercoagulability in patients with primary...
4.
Galea V, Khaterchi A, Robert F, Gerotziafas G, Hatmi M, Elalamy I
Platelets
. 2012 Sep;
24(6):441-7.
PMID: 22994796
Heparin-induced thrombocytopenia (HIT) is a potentially lethal adverse effect of heparin therapy. Accurate and rapid HIT laboratory diagnosis when HIT is suspected is crucial. The combination of an immunological assay...
5.
Gerotziafas G, Galea V, Mbemba E, Sassi M, Roman M, Khaterchi A, et al.
Curr Vasc Pharmacol
. 2012 Jun;
12(6):893-902.
PMID: 22724467
Low molecular weight heparins (LMWHs) and fondaparinux are widely used for prophylaxis and treatment of venous thromboembolic disease in cancer patients. However, the optimization of the antithrombotic treatment especially in...
6.
Karroum A, Mirshahi P, Faussat A, Therwath A, Mirshahi M, Hatmi M
Eur J Pharmacol
. 2012 May;
685(1-3):1-7.
PMID: 22542663
We have previously demonstrated that matrix metalloproteinase-9 (MMP-9) is critical for breast cancer cell migration and is necessary but not sufficient for tubular network formation. Given the important angiogenic activity...
7.
Gerotziafas G, Van Dreden P, Chaari M, Galea V, Khaterchi A, Lionnet F, et al.
Thromb Haemost
. 2012 Apr;
107(6):1044-52.
PMID: 22535498
Sickle cell disease (SCD) is linked to hypercoagulability and is characterised by high concentrations of erythrocyte-derived microparticles (Ed-MPs). However, the impact of procoagulant cell-derived microparticles on the thrombin generation process...
8.
Gerotziafas G, Baccouche H, Sassi M, Galea V, Chaari M, Hatmi M, et al.
Thromb Res
. 2011 Oct;
129(1):101-3.
PMID: 22000405
No abstract available.
9.
Gerotziafas G, Galea V, Mbemba E, Khaterchi A, Sassi M, Baccouche H, et al.
Thromb Res
. 2011 Sep;
129(6):779-86.
PMID: 21917301
Cancer histology influences the risk of venous thromboembolism and tissue factor (TF) is the key molecule in cancer-induced hypercoagulability. We investigated the relation between TF expression by pancreatic and breast...
10.
Chakroun T, Addad F, Yacoub S, Abderrezak F, Gerotziafas G, Abdelkafi S, et al.
Genet Test Mol Biomarkers
. 2011 Mar;
15(7-8):513-6.
PMID: 21434767
In this study, we evaluate the relationships between aspirin nonresponsiveness and the cyclooxygenase-1 (Cox-1) gene C50T polymorphism in stable coronary artery disease (CAD) in Tunisian patients. One hundred twenty-five stable...